Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Digital Healthcare in Cardiac Prevention Programme in Indonesia
Author(s): Bambang Dwiputra , Ade Meidian Ambari , Dwita Rian Desandri , et al Added: 11 months ago

Digital Health

Prevention & Chronic Conditions
Prevention: What's New at HFA 2025?
Author(s): Harriette Van Spall , Maja Cikes Added: 4 weeks ago
ESC HF 25 - Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Maja Cikes (University Hospital Centre Zagreb, HR) for an insightful wrap up of the novel data concerning preventive cardiology that was presented at 2025's Heart Failure Congress.Trials discussed include:REDICAE (00:42)FINEARTS HF (02:27)CRISPR Gene Editing with Nexiguran Ziclumeran (05:53)HELIOS B (07:12)RESHAPE… View more

Heart Failure
DOACs versus LMWH in Prevention of VTE Recurrence in Cancer Patients
Author(s): Patricia Noreen L Bueno , William Bernard N Ong , Frinz Moey C Rubio , et al Added: 1 month ago
Efficacy and Safety of LAAO during Cardiac Surgery to Prevent Stroke
Author(s): Reynald Evan R Tugade , Billy Joseph David , Clara S Tolentino Added: 8 months ago

Electrophysiology & Arrhythmia

Prevention & Chronic Conditions
AHA 23: Preventive Cardiology in 2023
Author(s): Michael Honigberg Added: 1 year ago
AHA 23 — Dr Michael Honigberg (Massachusetts General Hospital, US) highlights key 2023 cardiology updates, featuring novel data from AHA Scientific Sessions.Dr Honigberg provides commentary on the new SELECT trial outcomes and emphasises the incretin mimetic, semaglutide's role in cardiovascular medicine. He delves into lipid management with a focus on the CLEAR trial data and the incorporation… View more

Guidelines & Statements

Prevention & Chronic Conditions
Real-World Data for CV and Renal Outcomes in DKD
Author(s): David Wheeler Added: 1 week ago
ERA 2025 - Prof David Wheeler (University College London, London, UK) joins us to discuss outcomes from real-world data investigating cardiovascular and renal outcomes in patients with DKD.Interview Questions:1. How do real-world cardiovascular and renal outcomes compare to clinical trial results, and which data sources are giving us the best insights into DKD outcomes?2. What's the biggest gap… View more

Cardiovascular Renal Metabolic
COVID-19 and Cardiovascular Care in Asia-Pacific
Author(s): Mitsuaki Sawano , Misato Chimura , Jonathan Yap , et al Added: 10 months ago

Imaging & Diagnostics

Heart Failure
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 3 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
ESC 24: STEEER-AF: Stroke Prevention & Rhythm Control Therapy
Author(s): Dipak Kotecha Added: 9 months ago
ESC Congress 2024 — Improved patient-level adherence to guideline recommendations on heart rhythm control through healthcare professional education in patients with atrial fibrillation.Investigator, Dr Dipak Kotecha (University of Birmingham, UK) joins us in London to share key findings from the STEEER-AF study (NCT04396418).This prospective, cluster-randomized international study compared two… View more

Electrophysiology & Arrhythmia

Prevention & Chronic Conditions
ACC.24: Preventing Chemotherapy-Related Heart Damage in Patients with Breast Cancer and Lymphoma: PROACT
Author(s): David Austin Added: 1 year ago
ACC.24 — We are joined onsite by Dr David Austin (South Tees Hospitals NHS Foundation Trust, UK) to discuss the findings from the PROACT trial (NCT03265574).Anthracyclines used in the treatment of breast cancer cause damage to the muscle cells in the heart, resulting in cardiotoxicity.PROACT is a phase III randomised superiority trial of enalapril for the prevention of anthracycline-induced… View more

CV Disease in Special Populations